Allergy Therapeutics PLC 2022 AR2
The report highlights Allergy Therapeutics PLC's progress in its clinical development programs, specifically the start of the pivotal Phase III trial for Grass MATA MPL and the Phase I trial for VLP Peanut. Financially, the company reported a decrease in revenue to #72.8m for the year ended 30 June 2022, reflecting strategic portfolio streamlining. On the ESG front, the company implemented a new ESG governance framework, achieved ISO 14001 certification for its Spanish operations, and committed to reducing Scope 1 and 2 emissions by 45% by 2030.
Company: Allergy Therapeutics PLC
Sector: Health Care
Country: United Kingdom
Year: 2022
Type: AR2
Pages: 145
Allergy Therapeutics PLC
Annual Report And Accounts
The report highlights Allergy Therapeutics PLC's progress in its clinical development programs, specifically the start of the pivotal Phase III trial for Grass MATA MPL and the Phase I trial for VLP Peanut. Financially, the company reported a decrease in revenue to #72.8m for the year ended 30 June 2022, reflecting strategic portfolio streamlining. On the ESG front, the company implemented a new ESG governance framework, achieved ISO 14001 certification for its Spanish operations, and committed to reducing Scope 1 and 2 emissions by 45% by 2030.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jul 1, 2021 - Jun 30, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Energy Consumption
Women on Board
Employees